Veradermics Oral Minoxidil VDPHL01 Posts Positive Phase 3 Topline Results in Androgenetic Alopecia

Veradermics announced positive topline results from Study 304, a registrational Phase 3 trial of VDPHL01, a sustained-release oral minoxidil formulation, in androgenetic alopecia. After 6 months of treatment, mean hair count on the scalp increased by 28.6 hairs per square centimeter with once-daily dosing, 36.4 with twice-daily dosing, and 6.6 with placebo.